Our Mission

Over 29 million Americans, or roughly 10% of the population, are afflicted with diabetes mellitus (DM) which carries a sum of $245 billion in health-related costs. Over one quarter of those individuals are undiagnosed and therefore at risk for severe complications. Surprisingly, up to 25% of diabetic patients carry a lifetime risk of developing a diabetic foot ulcer, a condition plagued with poor healing, infections and ultimately, amputation. [1

Diabetics often suffer comorbidities such as peripheral vascular disease and neuropathy which gives way to the rapid and insidious development of foot ulcers. In the individuals whom remain untreated, 30% will require a lower limb amputation, and a staggering 50% of these amputees die within 5 years of surgery.[2]

We are developing a device that allows the physician to process extracted fat, thus creating an enhanced stem cell product that can be reinjected in common areas where ulcers form. If a diabetic foot ulcer has already formed, there is compelling evidence that our therapeutic can be injected in and around the wound to speed healing. [3,4]

References:

1. Statistics About Diabetes  [Available from: http://www.diabetes.org/diabetes-basics/statistics/?referrer=https://www.google.com/].

2. Wound Care Awareness Week 2016  [Available from: http://healogics.com/Wound-Care-Resource-Center/WCAW-Assets].

3. Qin HL, Zhu XH, Zhang B, Zhou L, Wang WY. Clinical Evaluation of Human Umbilical Cord Mesenchymal Stem Cell Transplantation After Angioplasty for Diabetic Foot. Exp Clin Endocrinol Diabetes. 2016.

4. Kinoshita K, Kuno S, Ishimine H, Aoi N, Mineda K, Kato H, et al. Therapeutic Potential of Adipose-Derived SSEA-3-Positive Muse Cells for Treating Diabetic Skin Ulcers. Stem Cells Transl Med. 2015;4(2):146-55.

  • Facebook - White Circle
  • Twitter - White Circle
  • LinkedIn - White Circle

© Syntr Health Technologies, INC. 2019 All Rights Reserved.